To See The Combined Efficacy Of Panchakarma therepies(Vamana and Virechana) and Shamana Chikitsa with Rohitakadi Choornam in one group and Shamana Chikitsa with Rohitakadi Choornam Alone in second group in The Management Of Pittashya Ashmari (Cholelithiasis).

A Comparative Study To Evaluate The Combined Efficacy Of Vamana, Virechana And Rohitakadi Choornam Versus Rohitakadi Choornam Alone In The Management Of Pittashya Ashmari (Cholelithiasis): An Open-Label Randomized Controlled Clinical Trial - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/095131

Enrollment

Registered

2025-09-19

Start date

Unknown

Completion date

Unknown

Last updated

2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K807- Calculus of gallbladder and bile duct without cholecystitis

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: - Confirmed Diagnosis: Patients diagnosed with cholelithiasis confirmed by ultrasonography showing gallstones. - Clinical Presentation: Patients exhibiting classical signs and symptoms of cholelithiasis (e.g., right upper quadrant pain, nausea, vomiting, dyspepsia). - Stone Location: Presence of stone(s) in any part of the hepato-biliary-pancreatic system. - Age Range: Patients aged between 20 to 60 years. - Demographic Neutrality: Selection irrespective of gender, religion, caste, or economic status. - Stone Characteristics: Solitary or multiple stones with size less than 3 cm.

Exclusion criteria

Exclusion criteria: Jaundice Cholecystitis Cholangitis CA gallbladder Pancreatitis Liver failure Uncontrolled Diabetes mellitus RBS equal to or more than 200 mg per dl Pregnant and lactating women. Age less than 20 years and more than 60 years. Patient who needs surgical intervention.

Design outcomes

Primary

Measure	Time frame
Reduction in gallstone size measured via ultrasound imaging.Timepoint: 1st at baseline,2nd after vamana and virechana, 3rd after treatment and 4th after followup	—

Secondary

Measure	Time frame
Improvement in clinical signs & symptoms. Changes in LFT & Lipid profile.Timepoint: 1st at base line,2nd after vamana & virechana, 3rd after treatment & 4th after followup	—

Countries

India

Contacts

Public ContactDr Sakshi

All India Institute of Ayurveda

santoshbhatted@rediffmail.com94140485459

Outcome results